UPCC 54417: Phase I/II study of pembrolizumab in patients with relapsed or refractory extranodal NK/T cell lymphoma (ENKTL) nasal type and EBV-associated diffuse large B cell lymphomas (EBV-DLBCL)
Enrolling By Invitation
99 years or below
All
Phase
2
35 participants needed
1 Location
Brief description of study
The purpose of this study is to determine the safety and tolerability of pembrolizumab in people with lymphoma whose lymphoma relapsed or did not respond after receiving at least one prior treatment for lymphoma. This study will also determine how well patients with lymphoma respond to pembrolizumab.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: lymphoma
-
Age: 99 years or below
-
Gender: All
Updated on
19 Feb 2024.
Study ID: 828872
If you need help finding a study or have any questions, please contact us at psom-ocr@pobox.upenn.edu
